whatsapp-logo+92 300 859 4219 , +92 300 859 1434

   Cash On Delivery is Available

whatsapp-logo+92 300 859 4219 , +92 300 859 1434

   Cash On Delivery is Available

Paxlovid therapy doesn’t cut back danger of lengthy COVID, research finds

A staff of researchers has discovered that Paxlovid (Nirmatrelvir-ritonavir) didn’t cut back the danger of creating lengthy COVID for vaccinated, non-hospitalized people throughout their first COVID-19 an infection. Additionally they discovered the next proportion of people than beforehand reported with rebound signs and test-positivity after taking Paxlovid.